The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD...
The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD.
In summary, AREDS2 recruited 4203 volunteers with the non-advanced form of AMD, and all subjects received broad-spectrum antioxidants (vitamin C, vitamin E, beta-carotene, zinc and copper [AREDS1 formulation or variations thereof]) with additional treatment of lutein (L) and zeaxanthin (Z) (Treatment 1), or omega-3 fatty acids (Treatment 2), or L and Z and omega-3 fatty acids (Treatment 3), or placebo.
In brief, the AREDS 2 investigators reported:
This summary was created by Professor John Nolan, PhD, Principal Investigator, Fulbright Scholar, Howard Fellow, ERC Fellow, Macular Pigment Research Group, Vision Research Centre, Waterford Institute of Technology, Ireland.
A more detailed summary will be published in an upcoming print issue of Ophthalmology Times Europe.